AbbVie Receives Two New FDA's Breakthrough Therapy Designations For Telisotuzumab Adizutecan In Colorectal Cancer, Non-Small Cell Lung Cancer

뉴스 본문을 불러오고 있어요.

AbbVie Receives Two New FDA's Breakthrough Therapy Designations For Telisotuzumab Adizutecan In Colorectal Cancer, Non-Small Cell Lung Cancer | 웨이프 WAPE

AbbVie Receives Two New FDA's Breakthrough Therapy Designations For Telisotuzumab Adizutecan In Colorectal Cancer, Non-Small Cell Lung Cancer

기사 요약

관련 종목

댓글 —